Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Niagen Bioscience (NAGE) over the last 14 years, with Q3 2025 value amounting to $64.3 million.

  • Niagen Bioscience's Cash & Equivalents rose 9843.82% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 9843.82%. This contributed to the annual value of $44.7 million for FY2024, which is 6344.01% up from last year.
  • Latest data reveals that Niagen Bioscience reported Cash & Equivalents of $64.3 million as of Q3 2025, which was up 9843.82% from $60.5 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Cash & Equivalents registered a high of $64.3 million during Q3 2025, and its lowest value of $13.3 million during Q3 2022.
  • In the last 5 years, Niagen Bioscience's Cash & Equivalents had a median value of $27.9 million in 2024 and averaged $33.3 million.
  • As far as peak fluctuations go, Niagen Bioscience's Cash & Equivalents surged by 22848.32% in 2021, and later plummeted by 5993.6% in 2022.
  • Over the past 5 years, Niagen Bioscience's Cash & Equivalents (Quarter) stood at $28.2 million in 2021, then fell by 27.56% to $20.4 million in 2022, then soared by 33.68% to $27.3 million in 2023, then skyrocketed by 63.44% to $44.7 million in 2024, then surged by 43.95% to $64.3 million in 2025.
  • Its Cash & Equivalents was $64.3 million in Q3 2025, compared to $60.5 million in Q2 2025 and $55.6 million in Q1 2025.